Consolidated Statements of Redeemable Convertible Preferred Stock and Equity (Deficit) - USD ($) $ in Thousands |
Total |
Astra Zeneca [Member] |
FibroGen Europe [Member] |
Senior Preferred Stock [Member] |
Senior Preferred Stock [Member]
Astra Zeneca [Member]
|
Senior Preferred Stock [Member]
FibroGen Europe [Member]
|
Junior Preferred Stock [Member] |
Junior Preferred Stock [Member]
Astra Zeneca [Member]
|
Junior Preferred Stock [Member]
FibroGen Europe [Member]
|
Common Stock [Member] |
Common Stock [Member]
Astra Zeneca [Member]
|
Common Stock [Member]
FibroGen Europe [Member]
|
Additional Paid-in Capital [Member] |
Additional Paid-in Capital [Member]
Astra Zeneca [Member]
|
Additional Paid-in Capital [Member]
FibroGen Europe [Member]
|
Accumulated Other Comprehensive Loss [Member] |
Accumulated Other Comprehensive Loss [Member]
Astra Zeneca [Member]
|
Accumulated Other Comprehensive Loss [Member]
FibroGen Europe [Member]
|
Accumulated Deficit [Member] |
Accumulated Deficit [Member]
Astra Zeneca [Member]
|
Accumulated Deficit [Member]
FibroGen Europe [Member]
|
Noncontrolling Interest [Member] |
Noncontrolling Interest [Member]
Astra Zeneca [Member]
|
Noncontrolling Interest [Member]
FibroGen Europe [Member]
|
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Balance at Dec. 31, 2012 | $ (46,252) | $ 168,436 | $ 136,313 | $ 132 | $ 37,606 | $ (167) | $ (247,836) | $ 27,700 | ||||||||||||||||
Balance, Shares at Dec. 31, 2012 | 38,340,182 | 46,460,057 | 13,167,138 | |||||||||||||||||||||
Net loss | (14,943) | $ 0 | $ 0 | $ 0 | 0 | 0 | (14,943) | 0 | ||||||||||||||||
Change in unrealized loss on investments | (2,676) | 0 | 0 | 0 | 0 | (2,676) | 0 | 0 | ||||||||||||||||
Foreign currency translation adjustments | (665) | 0 | 0 | 0 | 0 | (665) | 0 | 0 | ||||||||||||||||
Issuance of Series A Preferred to non-controlling interests | 175 | 0 | 0 | 0 | 0 | 0 | 0 | 175 | ||||||||||||||||
Stock options exercised | 84 | $ 0 | $ 0 | $ 0 | 84 | 0 | 0 | 0 | ||||||||||||||||
Stock options exercised , Shares | 0 | 0 | 34,126 | |||||||||||||||||||||
Stock-based compensation | 3,444 | $ 0 | $ 0 | $ 0 | 3,444 | 0 | 0 | 0 | ||||||||||||||||
Balance at Dec. 31, 2013 | (60,833) | $ 168,436 | $ 136,313 | $ 132 | 41,134 | (3,508) | (262,779) | 27,875 | ||||||||||||||||
Balance, Shares at Dec. 31, 2013 | 38,340,182 | 46,460,057 | 13,201,264 | |||||||||||||||||||||
Net loss | (59,504) | $ 0 | $ 0 | $ 0 | 0 | 0 | (59,504) | 0 | ||||||||||||||||
Change in unrealized loss on investments | (1,723) | 0 | 0 | 0 | 0 | (1,723) | 0 | 0 | ||||||||||||||||
Foreign currency translation adjustments | 2,082 | 0 | 0 | 0 | 0 | 2,082 | 0 | 0 | ||||||||||||||||
Stock options exercised | 1,694 | $ 0 | $ 0 | $ 5 | 1,689 | 0 | 0 | 0 | ||||||||||||||||
Stock options exercised , Shares | 0 | 0 | 539,971 | |||||||||||||||||||||
Stock-based compensation | 18,698 | $ 0 | $ 0 | $ 0 | 18,698 | 0 | 0 | 0 | ||||||||||||||||
Balance at Dec. 31, 2014 | 240,676 | $ 0 | $ 0 | $ 590 | 546,247 | (3,149) | (322,283) | 19,271 | ||||||||||||||||
Balance, Shares at Dec. 31, 2014 | 0 | 0 | 59,046,296 | |||||||||||||||||||||
Conversion of preferred stock to common stock | $ 168,436 | $ 0 | $ 0 | $ 0 | $ 339 | $ 10 | $ 304,410 | $ 8,594 | $ 0 | $ 0 | $ 0 | $ 0 | $ 0 | |||||||||||
Conversion of preferred stock to common stock | $ (168,436) | $ (136,313) | $ (8,604) | |||||||||||||||||||||
Conversion of preferred stock to common stock, shares | 0 | 0 | 33,919,954 | 958,996 | ||||||||||||||||||||
Conversion of preferred stock to common stock, shares | 0 | (38,340,182) | (46,460,057) | 0 | 0 | 0 | 0 | 0 | ||||||||||||||||
Initial Public Offering, net of underwriting discounts, commission and issuance costs | $ 151,826 | $ 0 | $ 0 | $ 93 | $ 151,733 | $ 0 | $ 0 | $ 0 | ||||||||||||||||
Initial Public Offering, net of underwriting discounts, commission and issuance costs, shares | 0 | 0 | 9,315,000 | |||||||||||||||||||||
Astra Zeneca private placement | $ 20,000 | $ 0 | $ 0 | $ 11 | $ 19,989 | $ 0 | $ 0 | $ 0 | ||||||||||||||||
Astra Zeneca private placement, Shares | 0 | 0 | 1,111,111 | |||||||||||||||||||||
Net loss | (85,779) | $ 0 | $ 0 | $ 0 | 0 | 0 | (85,779) | 0 | ||||||||||||||||
Change in unrealized loss on investments | (164) | 0 | 0 | 0 | 0 | (164) | 0 | 0 | ||||||||||||||||
Foreign currency translation adjustments | 1,662 | 0 | 0 | 0 | 0 | 1,662 | 0 | 0 | ||||||||||||||||
Stock options exercised | 10,112 | $ 0 | $ 0 | $ 24 | 10,088 | 0 | 0 | 0 | ||||||||||||||||
Stock options exercised , Shares | 0 | 0 | 2,361,633 | |||||||||||||||||||||
Stock-based compensation | 27,681 | $ 0 | $ 0 | $ 0 | 27,681 | 0 | 0 | 0 | ||||||||||||||||
Balance at Dec. 31, 2015 | 196,825 | $ 0 | $ 0 | $ 620 | 586,647 | (1,651) | (408,062) | 19,271 | ||||||||||||||||
Balance, Shares at Dec. 31, 2015 | 0 | 0 | 61,985,079 | |||||||||||||||||||||
Shares issued upon vesting of restricted stock units and purchases made under the employee stock purchase plan, shares | 0 | 0 | 456,355 | |||||||||||||||||||||
Shares issued upon vesting of restricted stock units and purchases made under the employee stock purchase plan | 2,595 | $ 0 | $ 0 | $ 5 | 2,590 | 0 | 0 | 0 | ||||||||||||||||
True up of issuance costs related to initial public offering and common stock sold by FibroGen Europe | 42 | 0 | 0 | 0 | 42 | 0 | 0 | 0 | ||||||||||||||||
Warrants exercised | $ 0 | $ 0 | $ 0 | $ 1 | $ (1) | $ 0 | $ 0 | $ 0 | ||||||||||||||||
Warrants exercised, Shares | 120,795 |